A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Cetuximab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Sep 2024 Planned End Date changed from 1 Aug 2024 to 1 Oct 2024.
- 21 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Aug 2024.
- 12 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.